Insulet (PODD) Reworks Debt Terms, Is It Still Trading At A Discount?
Insulet (PODD) recently reworked its credit agreement, converting $475 million of term loans into new debt with lower interest rates and expanding its revolving credit facility to $750 million. Despite a significant share price decline, the company's stock is still considered 23% undervalued, with a fair value of $171.91, according to an analysis based on its product roadmap and recurring revenue model. However, the narrative acknowledges risks related to type 2 user retention and potential recall-related quality issues.
(PODD) and the Role of Price-Sensitive Allocations
Insulet Corporation (NASDAQ: PODD) is showing weak sentiment across all time horizons, supporting a short bias with an exceptional 64.3:1 risk-reward setup. AI models have generated distinct trading strategies, including long, breakout, and risk hedging, tailored for different risk profiles. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term horizons, all indicating a weak signal strength for the stock.
Form 4 Insulet Corporation For: 2 October By Investing.com
This article announces the filing of a Form 4 for Insulet Corporation on October 2, 2026. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by corporate insiders. The article provides no further details about the content of the Form 4.
Form 4 Insulet Corporation For: 2 October By Investing.com
This article announces the filing of a Form 4 for Insulet Corporation on October 2. Form 4 is a U.S. Securities and Exchange Commission (SEC) form that must be filed by company insiders to report changes in their beneficial ownership of the company's stock. The article provides minimal detail beyond the announcement of the filing.
Form 4 Insulet Corporation For: 2 October By Investing.com
This article announces a Form 4 filing for Insulet Corporation on October 2, 2026. The content is very brief, providing only the title and date of the filing. It is surrounded by extensive navigation and market data, but the core information pertains solely to this specific regulatory document.
Form 4 Insulet Corporation For: 2 October
The article announces a Form 4 filing for Insulet Corporation on October 2nd. It is a brief financial news item from Investing.com, typical of regulatory filing notifications. The article itself contains minimal content beyond the title and company name, surrounded by various market data, unrelated news headlines, and navigation elements.
Stock units replace cash pay for Insulet (PODD) director Huffines, who received 178 units.
Insulet Corp. director Robert Luther Huffines received 178 Deferred Units on September 30, 2026, as compensation instead of cash. These units, valued at $130.47 per share, will convert into common shares on a one-for-one basis upon distribution. Following this transaction, Huffines' reported position in Insulet common stock is 2,627 shares.
A director receives 141 stock units instead of cash compensation at Insulet (PODD).
Insulet Corp director Jonathan Jay Mazelsky acquired 141 deferred common stock units on September 30, 2026, in lieu of cash compensation under the company's Deferred Compensation Plan for Non-Employee Directors. The stock units, valued at $130.47 per share, bring his post-transaction position to 1,496 shares. These units convert one-for-one into common stock upon distribution, which the director can elect to receive as a lump sum or in annual installments.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation announced it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026, before market opening. The company will host a conference call at 8:00 a.m. (Eastern Time) on the same day to discuss the results. Details for accessing the live call and subsequent replay will be available on Insulet's Investor Relations website.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation (NASDAQ: PODD) announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, before financial markets open. The company will also host a conference call at 8:00 a.m. (Eastern Time) on the same day, with details available on its Investor Relations website. Insulet is a medical device company specializing in tubeless insulin pump technology through its Omnipod® brand.
Press Release: Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation announced it will release its third-quarter 2026 financial results on Wednesday, November 4, 2026, after the market closes. The company will host a conference call and webcast to discuss these results at 4:30 p.m. ET on the same day. Investors and interested parties can access the webcast live or via replay.
Important Notice to Long-Term Shareholders of Beta Bionics,
Grabar Law Office is investigating claims on behalf of long-term shareholders of Beta Bionics, Better Home & Finance, Erasca, and Insulet Corporation. The investigations concern alleged breaches of fiduciary duties by officers and directors, with specific allegations including misleading statements about product issues for Beta Bionics and Insulet, financial performance for Better Home & Finance, and intellectual property/clinical trial comparisons for Erasca. Shareholders who held stock prior to specific dates are encouraged to contact Grabar Law Office to seek corporate reforms and potential compensation.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation (NASDAQ: PODD) announced it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026, before the financial markets open. Management will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results. The call details and an archive will be available on the Investor Relations section of the company's website.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insulet Corporation (PODD) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Insulet Corporation (NASDAQ: PODD). The firm encourages shareholders who purchased Insulet securities before May 21, 2026, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for class actions and derivative suits.
Net current asset value per share of Insulet Corporation – HAN:GOV
This article provides financial information for Insulet Corporation (GOV) traded on the Hannover Stock Exchange. It specifically highlights the net current asset value per share for the company. The page appears to be a financial data portal, offering an overview of the company's financials, news, and community insights.
Insulet stock falls 1.13 percent as guidance concerns persist
Insulet's stock fell 1.13% due to persistent guidance concerns, despite strong Q2 2026 revenue growth of 23.50%. The company lowered its full-year revenue growth guidance to 20.00-22.00% due to retention issues with type 2 customers in the U.S., though international Omnipod growth guidance was raised. Analysts remain divided on the stock, with RBC significantly reducing its price target.
Bronstein, Gewirtz & Grossman, LLC Encourages Insulet Corporation (PODD) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insulet Corporation (NASDAQ:PODD) on behalf of investors who purchased securities prior to May 21, 2026, and continue to hold them. The investigation focuses on potential corporate wrongdoing by the company and its officers/directors. The law firm is encouraging affected investors to contact them to assist with the investigation, noting that they represent investors on a contingency fee basis.
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
Oppenheimer reports that Insulet (PODD) anticipates facing new market entrants in 2027 and 2028, which are expected to create emerging headwinds for the company. This information is considered premium news, requiring a subscription to access the full details. The article is brief and references Coinbase for trading information.
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet is focusing on improving retention rates for Type 2 diabetes customers using its Omnipod system, particularly during the initial 90 days. The company is expanding the adoption of its automated insulin delivery (AID) systems globally, with plans for Omnipod 6 and a fully closed-loop system for Type 2 diabetes in the coming years. Insulet is also enhancing its digital health platform, Omnipod Discover, and addressing manufacturing issues to support its growth and market leadership.
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet is focusing on improving retention among its Type 2 diabetes customers using the Omnipod system, particularly during the initial 90 days. The company is implementing strategies like enhanced sampling, adjusted incentives, improved support teams, and a broader rollout of its Omnipod Discover digital platform. Insulet also anticipates significant growth from its upcoming Omnipod 6 in 2027, a fully closed-loop Type 2 system in 2028, and continued international expansion.
Insulet stock heads into the open after a 0.1 percent rise
Insulet stock closed at USD 135.16 on September 24, 2026, marking a 0.1 percent rise, but remained near its 52-week low. The company's shares are down 52 percent year to date. Insulet recently presented at the Bernstein Insights healthcare forum, discussing growth, customer retention, and its automated insulin delivery strategy.
Bronstein, Gewirtz & Grossman, LLC Encourages Insulet Corporation (PODD) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insulet Corporation (NASDAQ:PODD) on behalf of investors who purchased securities prior to May 21, 2026, and continue to hold them. The investigation seeks to determine if the company and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for additional information and to assist in the investigation.
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Insulet Corporation (PODD), a medical device company specializing in insulin delivery systems, has experienced a significant stock decline, underperforming the iShares U.S. Medical Devices ETF (IHI) and its rival, DexCom (DXCM). This underperformance is attributed to commercial friction in its Type 2 diabetes segment, lower-than-expected user retention rates, and increased competition, despite beating Q2 earnings expectations. Analysts, however, maintain a "Moderate Buy" rating with a potential upside.
STAAR Surgical Company (STAA) Stock Price, News, Quote & History
This article provides a comprehensive overview of STAAR Surgical Company (STAA), including its current stock price, financial performance, and company profile. It details the company's products, market statistics, earnings trends, analyst ratings, and key financial highlights. The article also compares STAAR's performance against the S&P 500 benchmark.
Insulet stock trades 60.9 percent below its 52-week high
Insulet stock (PODD) is trading 60.9 percent below its 52-week high, despite reporting strong Q2 2026 revenue growth of 22.7 percent to USD 801.7 million, exceeding guidance. The company maintained its full-year revenue growth outlook but adjusted its U.S. Omnipod growth lower while raising international Omnipod guidance. Insulet also increased its adjusted EPS growth outlook for the full year, indicating operating leverage.
Wells Fargo initiates Beta Bionics stock with overweight rating
Wells Fargo has initiated coverage on Beta Bionics Inc. (NASDAQ:BBNX) with an overweight rating and a price target of $28.00, anticipating strong revenue growth from the company's Mint product. The firm projects Mint to drive an approximate 38% revenue compound annual growth rate through 2030, with a significant increase in the penetration of tubeless pumps in the U.S. market. Despite recent wider-than-expected losses and a downward revision of fiscal 2026 guidance, the company has secured FDA clearance for its Mint patch pump and announced a $125 million stock offering.
Insulet stock heads into the open after a 0.8 percent drop
Insulet stock opened at $140.53 on September 22, 2026, marking a 0.8% drop, while the Nasdaq Composite rose by 0.45%. The stock is trading near its 52-week low, being 10.1% above the lowest point of $126.40. This article provides market data and context for Insulet's performance heading into the September 23, 2026 session.
Insulet Amends Credit Facilities, Expands Revolving Commitments
Insulet Corporation has amended its credit agreement, replacing $475 million in term loans at lower interest rates and expanding its revolving credit commitments by $250 million to $750 million. This move aims to reduce financing costs and enhance liquidity for the medical device company. TipRanks' AI Analyst, Spark, rates PODD as Neutral, noting strong financial performance tempered by free-cash-flow inconsistencies and U.S. type 2 retention issues.
Insulet stock holds at USD 140.53 near its yearly low
Insulet Corporation (ISIN US45784P1012) stock opened at USD 140.53 on September 22, 2026, close to its 52-week low of USD 126.40, marking a significant contraction from its yearly high of USD 354.88. Despite a strong Q2 2026 revenue growth of 23.5% year-over-year, beating analyst expectations, the stock's valuation is heavily influenced by its forward guidance, which missed expectations. The company's future stock performance largely depends on its ability to convert current revenue growth into more reliable future execution.
DexCom, Inc. (DXCM) stock price, news, quote and history
This page provides comprehensive financial information for DexCom, Inc. (DXCM), including its current stock price, historical data, and key financial metrics. It details the company's market performance, valuation measures, profitability, and allows for comparison with similar companies in the industry. The article also provides the stock's performance during regular and overnight trading sessions.
Insulet (PODD) cuts interest margins on $475M loan and expands credit access
Insulet Corporation (PODD) has refinanced $475 million in term debt, securing new loans with 0.25% lower interest margins. Additionally, the company increased its revolving credit facility by $250 million to a total of $750 million, also at reduced SOFR-based margins. These moves are expected to lower Insulet's borrowing costs and enhance its available liquidity for working capital and general corporate purposes.
Insulet Corporation Amends And Increases Credit Agreement, Refinances $475 Million Term Loans, And Expands Revolving Credit Facility To $750 Million
Insulet Corporation has amended and increased its credit agreement, refinancing $475 million in term loans and expanding its revolving credit facility to $750 million. The new term loans have a lower interest rate margin compared to the existing ones, and the revolving credit commitments were significantly increased with a reduced interest rate margin. These changes aim to provide Insulet Corporation with greater financial flexibility for working capital and general corporate purposes.
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insulet Corporation (NASDAQ:PODD) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Insulet Corporation securities prior to May 21, 2026, and still hold them, to contact them to learn more about the investigation. The firm operates on a contingency fee basis, only seeking reimbursement for expenses and fees if successful in recovering funds for investors.
Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow (NASDAQ:PODD) 2026-06-04
Insulet Corporation (PODD) presented a slideshow at the 46th Annual William Blair Growth Stock Conference. This article highlights the event, noting that the company published a slide deck in conjunction with its presentation. The content was provided by Seeking Alpha's transcripts team.
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Insulet Corporation announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on September 24, 2026, at 12:30 p.m. ET. The company, a leader in tubeless insulin pump technology with its Omnipod® brand, will have management present at the event. A live webcast and replay of the presentation will be available on Insulet's Investor Relations website.
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
Baron Capital's Baron SMID Cap ETF (BCSM) exited its position in Insulet Corporation (PODD) during the second quarter of 2026. The fund cited an accelerating competitive landscape and safety issues affecting Insulet's production as reasons for the sale, though it continues to admire the company and keeps it on its radar. Despite the exit, Insulet Corporation (PODD) is considered a global leader in tubeless automated insulin delivery devices, with significant market potential.
Insulet Faces Class Action Lawsuit Over Product Safety Issues
Insulet Corporation is facing a class action lawsuit from Bleichmar Fonti & Auld LLP, alleging the company made false statements about the safety of its Omnipod 5 product, which is linked to manufacturing defects and improper insulin delivery. This legal challenge has contributed to a significant drop in Insulet's stock price, hitting a 52-week low. The lawsuit highlights potential legal and financial risks that could impact the company's future sales and market position in the medical device industry.
3 Stocks Estimated To Be Priced Below Their Intrinsic Value In September 2026
The article identifies three US stocks—ChoiceOne Financial Services (COFS), Primis Financial (FRST), and Northeast Bank (NBN)—that are estimated to be trading below their intrinsic value as of September 2026, offering potential long-term investment opportunities. It highlights their current discounts to fair value, operational overviews, and key financial characteristics, such as dividends, earnings growth, and challenges. The analysis emphasizes cash flow-based valuation in a market with steady growth.
FDA Clears New Type of Insulin Patch Pump From Beta Bionics
The FDA has cleared Beta Bionics Inc.'s Mint, a new type of insulin patch pump that features a reusable and disposable architecture and does not require recharging. It integrates with Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus continuous glucose monitors and with both iOS and Android smartphones. Commercial launch is expected in the first quarter of 2027 exclusively through the pharmacy channel.
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
This article analyzes the Q2 earnings of patient monitoring stocks, focusing on ResMed (NYSE:RMD), iRhythm Technologies (NASDAQ:IRTC), Insulet (NASDAQ:PODD), and DexCom (NASDAQ:DXCM). It highlights their revenue performance against analyst expectations, stock reactions, and the broader industry trends including growth drivers like chronic disease prevalence and digital health, and challenges such as high R&D costs and pricing pressures. While the sector generally reported strong Q2 results, individual stock performances varied significantly post-earnings.
Important Notice to Long-Term Shareholders of FuelCell
Grabar Law Office is investigating claims on behalf of long-term shareholders of FuelCell Energy, Inc., Insulet Corporation, Papa John's International, Inc., and York Space Systems Inc. The investigations focus on potential breaches of fiduciary duties by company officers and directors, stemming from allegations of misleading statements or failures to disclose material adverse facts. Shareholders who held shares before specific dates are encouraged to contact Grabar Law Office for potential shareholder governance actions.
Insulet Corp. stock underperforms Friday when compared to competitors
Insulet Corp. (PODD) shares fell 2.02% to $131.96 on Friday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average both rose. This marked the fifth consecutive day of losses for Insulet's stock.
MiniMed Group (MMED) Stock Forecast and Price Target 2026
This article provides a stock forecast and price target for MiniMed Group (MMED) for 2026, based on analysis from 16 Wall Street analysts. The consensus rating is "Moderate Buy" with an average price target of $23.77, representing a potential upside of 5.64% from its current price. Recent analyst actions show several boosts to price targets, reflecting a generally positive outlook.
Baron SMID Cap ETF Q2 2026 Commentary (BCSM)
The Baron SMID Cap ETF (BCSM) underperformed its benchmark, the Russell 2500 Growth Index, in Q2 2026, primarily due to being underweight momentum and beta factors and a tilt towards mid-cap stocks. The ETF added Shake Shack Inc. to its portfolio while selling Insulet due to competitive landscape and safety concerns. Baron Capital, the firm managing the ETF, emphasizes a long-term, fundamental, active approach to growth investing.
Insulet: Omnipod Users Report Persistent Leakage, Under-Delivery Problems with Insulin Devices Not Included in Prior Recall
Insulet Corporation (PODD) is facing new reports of persistent leakage and under-delivery issues with its Omnipod insulin delivery devices. These problems are reported by users for devices not covered in a prior recall issued in May, which affected specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros due to a tubing tear causing insulin leakage. The article highlights ongoing concerns with the product's reliability.
State offers record $40M package to keep medical device company in Mass.
Massachusetts is offering a record $40 million job creation package to Insulet Corp., a medical device company, to prevent it from relocating. Insulet, founded in 2000, specializes in automated insulin delivery systems and reported $2.7 billion in revenue in 2025 with 5,400 employees. State officials are making this aggressive offer to retain the innovative firm in Massachusetts.
State offers record $40M package to keep Insulet Corp. in state
The Massachusetts Life Sciences Center has offered Insulet Corp. its largest-ever job creation package, valued at $40 million, to encourage the medical device maker to expand within the state. This move comes as Acton-based Insulet considers expanding its operations. The incentive aims to retain the growing company and its job opportunities in Massachusetts.
Insulet stock falls after weaker 2026 guidance
Insulet's stock declined after the company issued weaker revenue growth guidance for 2026, lowering its forecast from 21-23% to 20-22%. Additionally, its third-quarter revenue outlook of USD 833.4 million fell below analyst expectations. Despite strong second-quarter results with revenue up 23.5% to USD 801.7 million and adjusted EPS beating forecasts, the market's focus shifted to the softer full-year outlook.
Insulet Corp. stock underperforms Friday when compared to competitors
Insulet Corp. (PODD) stock fell 2.06% on Friday, closing at $147.48. This underperformance occurred during a general market downturn, with the S&P 500 Index and Dow Jones Industrial Average also declining. The company's stock is currently 58.44% below its 52-week high reached in November.
Baron SMID Cap ETF Q2 2026 Portfolio Activity
During the second quarter of 2026, the Baron SMID Cap ETF (BCSM) initiated a position in Advanced Drainage Systems and continued to view Axon Enterprise as a strong market leader. The fund exited positions in HeartFlow, Booz Allen, and Insulet due to increased competition and market concerns, reallocating capital to higher-conviction opportunities. Despite underperforming its benchmark, BCSM highlighted growth potential in companies like Shake Shack and Advanced Drainage Systems.
